Drug-coated stents less risky for heart bypass patients

Jan 22, 2009

Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found.

The study, appearing online and in an upcoming issue of The Journal of the American College of Cardiology, is the first large, multicenter trial comparing two types of commonly used stents. Stents are small mesh tubes that reinforce the walls of blocked blood vessels. In this study, stents were used to treat blockages in diseased coronary arteries.

In bypass surgery, grafts are taken from the saphenous vein in the patient's thigh and sewn to the coronary arteries to help improve blood flow to the heart, relieve severe chest pain and reduce the risk of heart attacks from blocked arteries. Years after surgery, those grafts may develop blockages inside the graft that are challenging to treat because of high rates of recurrence.

"We wanted to see if one type of stent was superior in reducing the incidence of re-narrowing of the vein graft," said Dr. Emmanouil Brilakis, assistant professor of internal medicine at UT Southwestern and lead author of the study. "Stented vein grafts have a very high risk of re-narrowing - sometimes up to 50 percent when bare metal stents are used.

"Drug-eluting stents could provide a solution to this problem, but limited clinical results have been reported to date. The drug-eluting stents examined in our study are coated with a medication called paclitaxel, which inhibits cell growth."

The drug coating is contained on a polymer that covers the surface of the stents and eventually elutes, or washes out of the stent, over a period of several months or years.

In the study, researchers examined 80 patients, roughly half of whom had vein grafts with drug-eluting stents and the other half who had the same procedure with bare-metal stents.

Researchers found that 51 percent of patients with the bare-metal stent had re-narrowing of the vein graft over several months compared with 9 percent of the drug-eluting stent group. In addition, 28 percent of patients who had a bare-metal stent required another procedure to treat the same blockage, while only 5 percent of patients who had the drug-eluting stent did.

Some previous studies have indicated that patients receiving drug-eluting stents in saphenous vein grafts may not reduce the risk of re-narrowing and may be associated with increased risk of death, Dr. Brilakis said.

"Our findings suggest that drug-eluting stents are a better choice than bare-metal stents for this type of procedure," he said. "Patients receiving paclitaxel-eluting stents in our study were significantly less likely to have recurrence of their graft blockage and to require repeat procedures. The rates of death were similar in both study groups, although our study was not designed to detect differences in mortality."

The researchers now hope to repeat the study in an expanded group of patients, which would provide important data to determine definitively the efficacy and safety of each kind of stent.

Source: UT Southwestern Medical Center

Explore further: The impact of bacteria in our guts

add to favorites email to friend print save as pdf

Related Stories

Diabetics get blood vessels made from donor cells

Jun 27, 2011

Three dialysis patients have received the world's first blood vessels grown in a lab from donated skin cells. It's a key step toward creating a supply of ready-to-use arteries and veins that could be used ...

Stem cell study aims to reduce amputations

Mar 09, 2011

UC Davis Vascular Center researchers have embarked on a highly anticipated study that involves using a patient's own stem cells to increase blood circulation to the lower leg with the hope of preventing amputation due to ...

Scientists grow blood vessels for human surgery

Feb 02, 2011

Scientists can grow blood vessels in a lab for use in coronary bypass or dialysis, a promising alternative to harvesting from the patient, said a study published on Wednesday.

Recommended for you

The impact of bacteria in our guts

Aug 22, 2014

The word metabolism gets tossed around a lot, but it means much more than whether you can go back to the buffet for seconds without worrying about your waistline. In fact, metabolism is the set of biochemical ...

Stem cell therapies hold promise, but obstacles remain

Aug 22, 2014

(Medical Xpress)—In an article appearing online today in the journal Science, a group of researchers, including University of Rochester neurologist Steve Goldman, M.D., Ph.D., review the potential and ch ...

New hope in fight against muscular dystrophy

Aug 22, 2014

Research at Stockholm's KTH Royal Institute of Technology offers hope to those who suffer from Duchenne muscular dystrophy, an incurable, debilitating disease that cuts young lives short.

Biologists reprogram skin cells to mimic rare disease

Aug 21, 2014

Johns Hopkins stem cell biologists have found a way to reprogram a patient's skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. ...

User comments : 0